The Patent Trial and Appeal Board determined that challenged claims of California Institute of Technology’s patent that relates to methods and kits for the multiplexed detection of analytes in a sample aren’t unpatentable as anticipated by or obvious over prior art, in an inter partes review by Bio-Rad Laboratories Inc. According to the board, the challenged claims aren’t anticipated by or obvious over prior art that relates to droplet based digital PCR and methods for analyzing a target nucleic acid, digital assays with multiplexed detection of two or more targets in the same optical channel, and a microfluidic device for ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.